May 9, 2021

Knews

Your News Buddy

In the first quarter, Pfizer earned $ 3.5 billion for the COVID-19 vaccine

The company has received $ 3.5 billion in the first three months of this year, which represents about a quarter of its total revenue, the company announced on Tuesday.

The drug giant He expects the vaccine to earn a total of $ 26 billion by 2021, based on contracts signed by mid-April, which called for 1.6 billion doses of the vaccine this year.

The company’s forecast was $ 15 billion a year, but revenue in the first quarter of 2021 alone saw an increase of $ 4.6 billion, or 45 percent, compared to $ 14.6 billion.

Unlike many other competing companies that developed COVID-19 vaccines, Pfizer did not use federal funds and said he was planning to make a profit. Democrat lawmakers and drug advocates have raised concerns about the professor’s decision, arguing that it could lead to higher prices after the first epidemic.

Johnson and Johnson and Astrazenica decided to sell their vaccines for non-profit during the epidemic. Moder and the vaccine were developed with the help of the federal government, but due to the lack of other products on the market, he decided not to sell the vaccine at a profit.

Pfizer expects to produce at least 2.5 billion doses by 2021 and will have an additional 3 billion doses by 2022, according to CEO Albert Burla.

As we have seen, we believe we have a lasting need for our COVID-19 vaccine Similar to flu vaccines That could be the result, ā€¯Burla said.

Pfizer said it plans to file a full approval from the Food and Drug Administration (FDA) later this month. The company said in the second half of July that it would like to apply for an emergency use license for a high-impact stroke that could prevent differences from COVID-19.

The New York Times Reported On Monday, the FDA is ready to issue permits for Pseudomonas aeruginosa vaccine to Pseudomonas and Biotech. And tThe company expects accurate test results and plans to get permission for the vaccine for children 2-5 years and 5-11 years old in September.

As of Monday, Pfizer, along with partner Biotech, had delivered 430 million vaccines to 91 countries and territories worldwide, Borla said.

But most PFZ vaccines are safe in developed countries. Although the company has promised millions of doses to the World Health Organization, critics are calling on Pfizer to do more.

Borla said the company is committed to making the COVID-19 vaccine global.

We hope that the Pfizer-BioNTech vaccine will continue to have a global impact, not only in controlling the epidemic and helping to keep economies around the world open – but also for Pfizer. Burla.

.